# SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 YTD Q2 P&L / Income Statement

- Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001356576-26-000037
- Page: https://plicit.ai/financials/supn/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/supn-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (9 categories)

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (9 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 426,763,000 US dollars
- **Cost of revenues**: 57,060,000 US dollars
- **Gross profit (calculated)**: 369,703,000 US dollars
- **Operating expenses (calculated)**: 435,998,000 US dollars
- **Operating earnings (loss)**: negative 66,295,000 US dollars
- **Total other income, net**: 2,697,000 US dollars
- **Earnings (loss) before income taxes**: negative 63,598,000 US dollars
- **Income tax expense (benefit)**: negative 2,934,000 US dollars
- **Net earnings (loss)**: negative 60,664,000 US dollars
- **Collaboration revenue (ZURZUVAE)**: 62,993,000 US dollars
- **Royalty, licensing, and other revenues**: 47,304,000 US dollars
- **Qelbree**: 167,082,000 US dollars
- **GOCOVRI**: 72,770,000 US dollars
- **ONAPGO**: 21,921,000 US dollars
- **Trokendi XR**: 17,890,000 US dollars
- **Oxtellar XR**: 16,204,000 US dollars
- **APOKYN**: 14,051,000 US dollars
- **Other**: 6,548,000 US dollars
- **Research and development**: 68,901,000 US dollars
- **Selling, general and administrative**: 258,810,000 US dollars
- **Amortization of intangible assets**: 50,977,000 US dollars
- **Intangible asset impairment charges**: 54,919,000 US dollars
- **Contingent consideration loss**: 2,391,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (3 categories)

- Page: https://plicit.ai/financials/supn/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-3-categories
- Chart image: https://plicit.ai/charts/supn-fy2026-ytd-q2-revenue-by-product-and-service-3-categories-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 426,763,000 US dollars
- **Cost of revenues**: 57,060,000 US dollars
- **Gross profit (calculated)**: 369,703,000 US dollars
- **Operating expenses (calculated)**: 435,998,000 US dollars
- **Operating earnings (loss)**: negative 66,295,000 US dollars
- **Total other income, net**: 2,697,000 US dollars
- **Earnings (loss) before income taxes**: negative 63,598,000 US dollars
- **Income tax expense (benefit)**: negative 2,934,000 US dollars
- **Net earnings (loss)**: negative 60,664,000 US dollars
- **Net product sales**: 316,466,000 US dollars
- **Collaboration revenue (ZURZUVAE)**: 62,993,000 US dollars
- **Royalty, licensing, and other revenues**: 47,304,000 US dollars
- **Research and development**: 68,901,000 US dollars
- **Selling, general and administrative**: 258,810,000 US dollars
- **Amortization of intangible assets**: 50,977,000 US dollars
- **Intangible asset impairment charges**: 54,919,000 US dollars
- **Contingent consideration loss**: 2,391,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.